Aemetis (NASDAQ:AMTX) Stock Price Crosses Below 200-Day Moving Average - Time to Sell?

Aemetis, Inc (NASDAQ:AMTX - Get Free Report) shares crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.07 and traded as low as $1.90. Aemetis shares last traded at $2.14, with a volume of 1,125,604 shares changing hands.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on AMTX. UBS Group reduced their price objective on Aemetis from $2.50 to $2.20 and set a "buy" rating on the stock in a research note on Friday, May 9th. HC Wainwright restated a "buy" rating and issued a $28.00 price target on shares of Aemetis in a research report on Friday, March 14th. Finally, Ascendiant Capital Markets upped their price target on shares of Aemetis from $19.00 to $20.00 and gave the company a "buy" rating in a research note on Friday, June 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $13.43.

Aemetis Trading Up 1.4%

The firm has a 50-day moving average of $1.62 and a 200-day moving average of $2.06. The stock has a market capitalization of $120.15 million, a price-to-earnings ratio of -1.16 and a beta of 1.48.

Aemetis (NASDAQ:AMTX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The specialty chemicals company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.08). The company had revenue of $42.89 million during the quarter, compared to the consensus estimate of $59.35 million. During the same period in the prior year, the company posted ($0.58) EPS. On average, equities research analysts anticipate that Aemetis, Inc will post -2.07 EPS for the current year.

Institutional Trading of Aemetis

Several large investors have recently added to or reduced their stakes in AMTX. Price T Rowe Associates Inc. MD raised its position in Aemetis by 16.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 38,016 shares of the specialty chemicals company's stock valued at $103,000 after purchasing an additional 5,281 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Aemetis by 128.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,407 shares of the specialty chemicals company's stock worth $28,000 after purchasing an additional 5,859 shares during the period. Barclays PLC increased its holdings in Aemetis by 14.7% in the 4th quarter. Barclays PLC now owns 54,492 shares of the specialty chemicals company's stock valued at $146,000 after purchasing an additional 6,996 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Aemetis by 20.0% in the 4th quarter. Wells Fargo & Company MN now owns 45,741 shares of the specialty chemicals company's stock valued at $123,000 after purchasing an additional 7,622 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new stake in Aemetis in the 4th quarter valued at approximately $27,000. 27.02% of the stock is currently owned by hedge funds and other institutional investors.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.